CC-90011   Click here for help

GtoPdb Ligand ID: 11284

Synonyms: CC90011 | compound 11 [PMID: 33034194]
PDB Ligand
Compound class: Synthetic organic
Comment: CC-90011 is a clinical stage, selective lysine specific demethylase 1 (LSD1) inhibitor [4]. It is a reversible inhibitor. LSD1 inhibitors have potential to treat certain cancers [1-2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 97.17
Molecular weight 451.18
XLogP 5.23
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES N#Cc1ccc(cc1F)c1nc(N2CCC(CC2)N)n(c(=O)c1c1ccc(c(c1)F)OC)C
Isomeric SMILES N#Cc1ccc(cc1F)c1nc(N2CCC(CC2)N)n(c(=O)c1c1ccc(c(c1)F)OC)C
InChI InChI=1S/C24H23F2N5O2/c1-30-23(32)21(14-5-6-20(33-2)19(26)11-14)22(15-3-4-16(13-27)18(25)12-15)29-24(30)31-9-7-17(28)8-10-31/h3-6,11-12,17H,7-10,28H2,1-2H3
InChI Key NBAIXBAUHIQQGF-UHFFFAOYSA-N
References
1. Fang Y, Liao G, Yu B. (2019)
LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
J Hematol Oncol, 12 (1): 129. [PMID:31801559]
2. Fu X, Zhang P, Yu B. (2017)
Advances toward LSD1 inhibitors for cancer therapy.
Future Med Chem, 9 (11): 1227-1242. [PMID:28722477]
3. Hollebecque A, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, Curigliano G, Moreno V, Martin-Romano P, Baudin E et al.. (2021)
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.
Clin Cancer Res, 27 (2): 438-446. [PMID:33046517]
4. Kanouni T, Severin C, Cho RW, Yuen N Y-Y, Xu J, Shi L, Del Rosario JR, Stansfield RK, Lawton LN, Hosfield D et al.. (2020)
Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1).
J Med Chem, [Online ahead of print]. DOI: 10.1021/acs.jmedchem.0c00978 [PMID:33034194]